Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Progressive multi-focal leukoencephalopathy may represent emerging complication in pts receiving bispecifics due to combined effect of advanced disease, cumulative immunosuppression and treatment-related immune dysfunction.”
Title: Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy
Authors: Jean-Roch Le Henaff, Loïc Le Guennec, Pauline Schiro, Kevin Bihan, Jacques Gasnault, Bruno Stankoff, Yassine Taoufik, Emmanuel Treiner, Daniele Bensoussan, Sebastien Lhomme, Anne-Sophie L’Honneur, Fabrice Bonneville, Natalia Shor, Valérie Pourcher, Béatrice Pignolet, Baptiste Lievin, Clément Javaux, Julien Le Guen, Eolia Brissot, Pierre-Antoine Limouzin, Clémence Richaud, Bruno Lioure, Thomas Wirth, Paul Petitgas, Simon Herbel, François Coustillères, Elena-Camelia Rusu, Laura Maerten, Aurore Perrot, Agnès Sommet, Damien Roos-Weil, Margaux Lafaurie, Nicolas Weiss, Guillaume Martin-Blondel
You can read the Full Article on Blood Advances.
You can find other articles featuring Robert Orlowski on OncoDaily.
